FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:1774-1778 December 17, 1992 Number 25 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Agarwal, R. PubMed Citation

Abstract

BACKGROUND. Severe renal vasoconstriction is central to the pathogenesis of renal failure in the hepatorenal syndrome. Endothelin-1 and endothelin-3 are potent, long-acting vasoconstrictors, and endothelin-1 has selective potency as a renal vasoconstrictor. These properties suggest a role for endothelins in the hepatorenal syndrome. METHODS. We measured plasma endothelin-1 and endothelin-3 concentrations using specific radioimmunoassays in subjects with hepatorenal syndrome, liver disease but normal renal function, chronic renal failure, acute renal failure, liver dysfunction and renal impairment, or normal liver and kidney function. RESULTS. The patients with the hepatorenal syndrome had markedly elevated mean (+/- SE) plasma concentrations of endothelin-1 (36 +/- 5 ng per liter [14.5 +/- 1.8 pmol per liter]) and endothelin-3 (43 +/- 3 ng per liter [16.3 +/- 1.0 pmol per liter]) as compared with the normal subjects (endothelin-1, 4 +/- 1 ng per liter [1.7 +/- 0.2 pmol per liter]; and endothelin-3, 18 +/- 1 ng per liter [6.8 +/- 0.4 pmol per liter]; P < 0.001) and with the patients in the other four groups (P < 0.001 to P < 0.05). The plasma endothelin-1, but not endothelin-3, concentrations in these four patient groups were significantly higher than in the normal subjects (P < 0.001 to P < 0.05). The concentrations of endothelin-1 in renal arterial plasma and renal venous plasma, measured in five patients with the hepatorenal syndrome and three with chronic liver disease and normal renal function, were 20 +/- 4 ng per liter (7.9 +/- 1.8 pmol per liter) and 24 +/- 4 ng per liter (9.5 +/- 1.5 pmol per liter), respectively (P < 0.05). CONCLUSIONS. The increase in plasma endothelin-1 and endothelin-3 concentrations in patients with the hepatorenal syndrome is consistent with the hypothesis that these substances have a role in the pathogenesis of the disease.

Source Information

Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, United Kingdom.

This article has been cited by other articles:

• Angus, P W (2006). Role of endothelin in systemic and portal resistance in cirrhosis.. Gut 55: 1230-1232 [Full Text]  
• Tripathi, D, Therapondos, G, Ferguson, J W, Newby, D E, Webb, D J, Hayes, P C (2006). Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. Gut 55: 1290-1295 [Abstract] [Full Text]  
• Moore, K (2004). Endothelin and vascular function in liver disease. Gut 53: 159-161 [Abstract] [Full Text]  
• Luo, B., Liu, L., Tang, L., Zhang, J., Ling, Y., Fallon, M. B. (2004). ET-1 and TNF-{alpha} in HPS: analysis in prehepatic portal hypertension and biliary and nonbiliary cirrhosis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G294-G303 [Abstract] [Full Text]  
• Budhiraja, R., Hassoun, P. M. (2003). Portopulmonary Hypertension: A Tale of Two Circulations. Chest 123: 562-576 [Abstract] [Full Text]  
• Reynaert, H, Thompson, M G, Thomas, T, Geerts, A (2002). Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 50: 571-581 [Abstract] [Full Text]  
• Anand, R, Harry, D, Holt, S, Milner, P, Dashwood, M, Goodier, D, Jarmulowicz, M, Moore, K (2002). Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure. Gut 50: 111-117 [Abstract] [Full Text]  
• DAGHER, L, MOORE, K (2001). The hepatorenal syndrome. Gut 49: 729-737 [Full Text]  
• Gulberg, V, Moller, S, Henriksen, J H, Gerbes, A L (2000). Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure. Gut 47: 852-857 [Abstract] [Full Text]  
• Brensing, K A, Textor, J, Perz, J, Schiedermaier, P, Raab, P, Strunk, H, Klehr, H U, Kramer, H J, Spengler, U, Schild, H, Sauerbruch, T (2000). Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47: 288-295 [Abstract] [Full Text]  
• Zhang, M., Luo, B., Chen, S.-J., Abrams, G. A., Fallon, M. B. (1999). Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am. J. Physiol. Gastrointest. Liver Physiol. 277: G944-G952 [Abstract] [Full Text]  
• Dupuis, J., Schwab, A. J., Simard, A., Cernacek, P., Stewart, D. J., Goresky, C. A. (1999). Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 277: G905-G914 [Abstract] [Full Text]  
• Sort, P., Navasa, M., Arroyo, V., Aldeguer, X., Planas, R., Ruiz-del-Arbol, L., Castells, L., Vargas, V., Soriano, G., Guevara, M., Gines, P., Rodes, J. (1999). Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. NEJM 341: 403-409 [Abstract] [Full Text]  
• RUSCHITZKA, F., SHAW, S., GYGI, D., NOLL, G., BARTON, M., LÜSCHER, T. F. (1999). Endothelial Dysfunction in Acute Renal Failure: Role of Circulatingand Tissue Endothelin-1. J. Am. Soc. Nephrol. 10: 953-962 [Abstract] [Full Text]  
• Shao, R., Yan, W., Rockey, D. C. (1999). Regulation of Endothelin-1 Synthesis by Endothelin-converting Enzyme-1 during Wound Healing. J. Biol. Chem. 274: 3228-3234 [Abstract] [Full Text]  
• Mayer, D.C. G., Leinwand, L. A. (1997). Sarcomeric Gene Expression and Contractility in Myofibroblasts. JCB 139: 1477-1484 [Abstract] [Full Text]  
• Greenberg, S. G., Baker, R. S., Yang, D., Clark, K. E. (1997). Effects of Continuous Infusion of Endothelin-1 in Pregnant Sheep. Hypertension 30: 1585-1590 [Abstract] [Full Text]  
• Hasdai, D., Erez, E., Gil-Ad, I., Raanani, E., Sclarovsky, S., Barak, Y., Sulkes, J., Vidne, B. A. (1996). IS THE HEART A SOURCE FOR ELEVATED CIRCULATING ENDOTHELIN LEVELS DURING AORTA--CORONARY ARTERY BYPASS GRAFTING SURGERY IN HUMAN BEINGS?. J. Thorac. Cardiovasc. Surg. 112: 531-536 [Abstract] [Full Text]  
• Kaasjager, K. A. H., Koomans, H. A., Rabelink, T. J. (1995). Effectiveness of Enalapril Versus Nifedipine to Antagonize Blood Pressure and the Renal Response to Endothelin in Humans. Hypertension 25: 620-625 [Abstract] [Full Text]  
• Agarwal, R., Nurnberger, W., Moore, K. (1993). Plasma Endothelin and the Hepatorenal Syndrome. NEJM 329: 63-63 [Full Text]  
• (1992). A POSSIBLE CAUSE OF HEPATORENAL SYNDROME. JWatch General 1992: 2-2 [Full Text]  
• Xiong, Y., Tanaka, H., Richardson, J. A., Williams, S. C., Slaughter, C. A., Nakamura, M., Chen, J.-L., Yanagisawa, M. (2001). Endothelin-1 Stimulates Leptin Production in Adipocytes. J. Biol. Chem. 276: 28471-28477 [Abstract] [Full Text]